VANCOUVER, British Columbia, Sept. 26, 2017 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (OTC: MYMMF) (the "Company"or "MYM") is pleased to announce that it has finalized the lease agreement on building space for expansion into Phase B of the Laval, QC project.
Effective October 1, 2017 MYM will
Engineering plans for Phase B will be submitted to the Government of Laval by November 1, 2017. Expansion plans will subsequently be submitted to Health Canada to include the Phase B facility under the Phase A license that is currently under consideration.
"Finalizing the lease on additional space located adjacent to the existing Phase A facility enables MYM to substantially increase potential growing space of the Laval project," said Rob Gietl, CEO of MYM. "We are confident that Health Canada will consider the additional space in our current license application."
The Company also announces the approval and adoption of its Advance Notice Policy, by shareholders, at its Special Meeting held on September 13, 2017. The full text of the Policy is available at the Company's website (www.mymarijuana.ca).
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO MYM Nutraceuticals Inc.www.mymarijuana.ca
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
Contact: Investor Relations: +1-855-696-2261
View original content:http://www.prnewswire.com/news-releases/mym-finalizes-lease-agreement-on-building-for-phase-b-of-laval-qc-project-300525704.html
SOURCE MYM Nutraceuticals Inc.
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All